Healthy
Conditions
Keywords
botulinum toxin, botulism
Brief summary
A Phase 1, randomized, double-blind, placebo-controlled dose escalation trial of four dose cohorts of 10 subjects (1: 10mg, 2: 25mg, 3: 50mg, 4: 100mg).
Detailed description
A Phase 1, randomized, double-blind, placebo-controlled dose escalation trial of four dose cohorts of 10 subjects (1: 10mg, 2: 25mg, 3: 50mg, 4: 100mg). Dose escalation will not occur until safety data through Day 8 is reviewed by the Safety Review Committee (SRC). The study will consist of a twenty-eight day screening period, 12-hour clinic stay, and 120-day (Cohorts 1-3) or 180-day (Cohort 4) outpatient follow-up. The primary objective of this study is to assess the safety and tolerability of escalating doses of G03-52-01 administered intramuscularly (IM) in healthy adult subjects. The secondary objectives are to evaluate the pharmacokinetics (PK) and immunogenicity of escalating IM doses of G03-52-01.
Interventions
DRUGG03-52-01
G03-52-01 administered intramuscularly
DRUGPlacebo
Placebo administered intramuscularly
Sponsors
United States Department of Defense
Alachua Government Services, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
randomized, double-blind, placebo-controlled
Intervention model description
dose escalation trial of four dose cohorts of 10 subjects (A: 10mg, B: 25mg, C: 50mg, D: 100 mg)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Informed consent understood and signed 2. Healthy male or healthy, non-pregnant, non-lactating female 3. Willingness to comply and be available for all protocol procedures 4. Between 18 and 45 years of age on the day of IM injection 5. Body Mass Index (BMI) of ≥18.5 and ≤35 kg/m2 6. If the subject is female and of childbearing potential, she has a negative serum pregnancy test at screening and negative urine test within 24 hours prior to IM injection • Note: A woman is considered of childbearing potential unless post-menopausal (≥ 1 year without menses) or surgically sterilized via bilateral oophorectomy, or hysterectomy or bilateral tubal ligation or successful Essure placement with documented confirmation test at least 3 months after the procedure. 7. If the subject is female and of childbearing potential, she agrees to practice abstinence from sexual intercourse with men or use acceptable contraception during participation in the study • Note: Acceptable contraception methods are restricted to effective devices (Intrauterine Contraceptive Devices) 8. The hemoglobin, platelet count, white blood cell count and absolute neutrophil count are not below the LLN and ≤ULN x 10% • Abnormalities in mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), mean platelet volume (MPV), and nucleated red blood cell count (NRBC CT), which are included in a complete blood count with differential, will not be exclusions. 9. The urine dipstick results on protein, glucose and blood are negative or trace * Note: Menstruating females failing inclusion criteria due to a positive blood on urine dipstick may be retested following cessation of menses. * Note: When a urine dipstick is more than trace positive for blood (whether a menstruating female or other subjects), that subject would not be excluded if the urine microscopic exam shows \<5 rbcs/hpf. 10. Chemistry screening laboratory tests as outlined in Section 7.5.1.4 are in the normal reference range * Note: The following exceptions to laboratory normal reference ranges are allowed: Creatinine, Blood Urea Nitrogen (BUN), total bilirubin, AST, ALT, lipase, amylase, Prothrombin Time (PT), Partial Thromboplastin Time (PTT) below the lower limit of normal (LLN); CK less than 400U/L; Glucose, potassium, total protein, and alkaline phosphatase with a toxicity grade of 1 is allowable; albumin above the upper limit of normal (ULN). * Laboratory values that are outside the range of eligibility but are thought to be due to an acute condition or due to laboratory error may be repeated once. 11. The urine drug screen is negative 12. Breathalyzer test is negative 13. Available for follow-up for the duration of the study 14. Agrees not to participate in vigorous activity 72 hours prior to dosing through day 15 post dosing
Exclusion criteria
1. History of a chronic medical condition that would either interfere with the accurate assessment of the objectives of the study or increase the risk profile of the subject. • Note: Chronic medical conditions include but not limited to diabetes; Asthma requiring use of medication in the year before screening; Autoimmune disorder such as lupus, Wegener's, rheumatoid arthritis, thyroid disease; Coronary artery disease; Chronic hypertension; History of malignancy except low-grade (squamous and basal cell) skin cancer thought to be cured; chronic renal, hepatic, pulmonary, or endocrine disease (except previous asthma which has required no treatment for the past year); 2. History of severe allergic reaction of any type to medications, bee stings, food, or environmental factors or hypersensitivity or reaction to immunoglobulins. • Note: Severe allergic reaction is defined as any of the following: anaphylaxis, urticaria, or angioedema 3. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 milliseconds) 4. Clinically significant abnormal electrocardiogram at screening. • Note: Clinically significant abnormal ECG results include but not limited to: complete left or right bundle branch block; other ventricular conduction block; 2nd degree or 3rd degree atrioventricular (AV) block; sustained ventricular arrhythmia; sustained atrial arrhythmia; two Premature Ventricular Contractions in a row; pattern of ST elevation felt consistent with cardiac ischemia; or any condition deemed clinically significant by a study investigator 5. Positive serology results for HIV, HBsAg, or HCV antibodies 6. Febrile illness with temperature ≥38°C within 7 days of dosing 7. Pregnant or breastfeeding 8. Donated blood within 56 days of enrollment 9. Known allergic reactions to any of the study product components present in the formulation or in the processing, as listed in the Investigator Brochure 10. Treatment with another investigational drug within 28 days of dosing 11. Treatment with a monoclonal antibody within 3 months of enrollment. 12. Receipt of antibody (e.g. TIG, VZIG, IVIG, IM gamma globulin) or blood transfusion within 6 months or within 5 half-lives of the specific product given 13. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements 14. Use of H1 antihistamines or beta-blockers within 5 days of dosing 15. Use of any prohibited medication within 28 days prior to study entry or planned use during the study period • Note: Prohibited medications include immunosuppressives (except Nonsteroidal Anti-Inflammatory Drugs \[NSAIDS\]); immune modulators; oral corticosteroids (topical/intranasal steroids are acceptable); anti-neoplastic agents; any vaccine (licensed or investigational). Subjects will be eligible to receive any authorized COVID-19 vaccine after they complete Study Day 8 16. Previous exposure to botulinum toxin, receipt of antibodies against botulinum toxin, or previous treatment with equine antitoxin 17. Any previous injection or planned injection within 4 months after enrollment of botulinum toxin for cosmetic reasons, spastic dysphonia, torticollis, or any other reason 18. Any specific condition that in the judgment of the investigator precludes participation because it could affect subject safety 19. Plans to enroll or is already enrolled in another clinical trial\* that could interfere with safety assessment of the investigational product at any time during the study period • Note: Includes trials that have a study intervention such as a drug, biologic, or device 20. Is a study site employee or staff • Note: Site employees or staff include the PIs and sub-investigators or staff who are supervised by the PI or Sub-Investigators 21. Systolic blood pressure \>140mm Hg or diastolic blood pressure \>90 mm Hg 22. Resting hear rate \<50 or \>100 beats per minute 23. Oral temperature ≥ 38°C (100.4°F) 24. Subjects with NX02 antibody levels present at screening will be excluded from Cohort 4.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit. | day 0 to day 120 | Determine number of SAEs after dosing (Cohorts 1-3) |
| The Occurrence of Adverse Events (AE) Following Administration of G03-52-01 to the Final Follow-up Visit | day 0 to day 120 | Determine number of AEs after dosing (Cohorts 1-3) |
| The Occurrence of Changes From Baseline in Physical Examination, Vital Signs and Clinical Safety Laboratory Values Following Administration of G03-52-01 to the Final Follow-up Visit. | day 0 to day 120 | Determine number of changes from baseline (Cohorts 1-3) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serotype B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | pre-dose, days 4, 30, 60, 90, and 120 | MNA assessment of PD (Cohorts 1-3) |
| Serotype A Area Under the Plasma Concentration Versus Time Curve (AUC) | pre-dose, days 4, 30, 60, 90, and 120 | MNA assessment of PD (Cohorts 1-3) |
| Serotype B Area Under the Plasma Concentration Versus Time Curve (AUC) | pre-dose, days 4, 30, 60, 90, and 120 | MNA assessment of PD (Cohorts 1-3) |
| Anti-BoNT A Peak Plasma Concentration (Cmax) | pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection, and on days 4, 8, 15, 30, 45, 60, 90, and 120 | ELISA/ECLA assessment of PK (Cohorts 1-3) |
| Anti-BoNT B Peak Plasma Concentration (Cmax) | pre-injection, 6 hours post injection, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180 | ELISA/ECLA assessment of PK (Cohort 4) |
| Serotype A Peak Plasma Concentration (Cmax) | pre-dose, days 4, 30, 60, 90, and 120 | MNA assessment of PD (Cohorts 1-3) |
| Anti-BoNT B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection, and on days 4, 8, 15, 30, 45, 60, 90, and 120 | ELISA/ECLA assessment of PK (Cohorts 1-3) |
| Anti-BoNT A Area Under the Plasma Concentration Versus Time Curve (AUC) | pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection, and on days 4, 8, 15, 30, 45, 60, 90, and 120 | ELISA/ECLA assessment of PK (Cohorts 1-3) |
| Anti-BoNT B Area Under the Plasma Concentration Versus Time Curve (AUC) | pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection and on days 4, 8, 15, 30, 45, 60, 90, and 120 | ELISA/ECLA assessment of PK (Cohort 1-3) |
| Anti-drug Antibodies (ADA) | pre-dose, days 15, 30, 45, 60, 90, and 120 | To assess the number of participants with positive anti-drug antibody levels (Cohorts 1-3) |
| Anti-BoNT A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection, and on days 4, 8, 15, 30, 45, 60, 90, and 120 | ELISA/ECLA assessment of PK (Cohorts 1-3) |
| Serotype B Peak Plasma Concentration (Cmax) | pre-dose, days 4, 30, 60, 90, and 120 | MNA assessment of PD (Cohorts 1-3) |
| Serotype A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | pre-dose, days 4, 30, 60, 90, and 120 | MNA assessment of PD (Cohorts 1-3) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 10mg of G03-52-01 8 subjects randomized to 10 mg of G03-52-01
G03-52-01: G03-52-01 administered intramuscularly | 7 |
| 25mg of G03-52-01 8 subjects randomized to 25 mg of G03-52-01
G03-52-01: G03-52-01 administered intramuscularly | 8 |
| 50 mg of G03-52-01 8 subjects randomized to 50 mg of G03-52-01
G03-52-01: G03-52-01 administered intramuscularly | 8 |
| 100 mg of G03-52-01 8 subjects randomized to 100 mg of G03-52-01
G03-52-01: G03-52-01 administered intramuscularly | 8 |
| Pooled Placebo 2 subjects randomized to placebo in each of the 4 cohorts/dosing groups
Placebo: Placebo administered intramuscularly | 8 |
| Total | 39 |
Baseline characteristics
| Characteristic | 10mg of G03-52-01 | 25mg of G03-52-01 | 50 mg of G03-52-01 | 100 mg of G03-52-01 | Pooled Placebo | Total |
|---|---|---|---|---|---|---|
| Age, Continuous | 34.1 years STANDARD_DEVIATION 9.58 | 33.9 years STANDARD_DEVIATION 6.69 | 35.8 years STANDARD_DEVIATION 6.58 | 34 years STANDARD_DEVIATION 4.04 | 36.3 years STANDARD_DEVIATION 6.98 | 34.8 years STANDARD_DEVIATION 6.77 |
| Body Mass Index (kg/m2) | 27.47 kg/m^2 STANDARD_DEVIATION 3.638 | 27.70 kg/m^2 STANDARD_DEVIATION 4.419 | 28.44 kg/m^2 STANDARD_DEVIATION 5.098 | 30.06 kg/m^2 STANDARD_DEVIATION 1.907 | 31.03 kg/m^2 STANDARD_DEVIATION 2.841 | 28.94 kg/m^2 STANDARD_DEVIATION 3.58 |
| Height | 165.39 cm STANDARD_DEVIATION 11.347 | 165.05 cm STANDARD_DEVIATION 5.19 | 161.45 cm STANDARD_DEVIATION 9.441 | 171.48 cm STANDARD_DEVIATION 10.268 | 167.86 cm STANDARD_DEVIATION 11.281 | 166.25 cm STANDARD_DEVIATION 9.51 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Black or African American | 2 Participants | 1 Participants | 0 Participants | 2 Participants | 1 Participants | 6 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 4 Participants | 4 Participants | 7 Participants | 4 Participants | 5 Participants | 24 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 3 Participants | 4 Participants | 1 Participants | 4 Participants | 3 Participants | 15 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White | 5 Participants | 7 Participants | 8 Participants | 6 Participants | 7 Participants | 33 Participants |
| Sex: Female, Male Female | 4 Participants | 4 Participants | 6 Participants | 3 Participants | 5 Participants | 22 Participants |
| Sex: Female, Male Male | 3 Participants | 4 Participants | 2 Participants | 5 Participants | 3 Participants | 17 Participants |
| Weight | 75.77 kg STANDARD_DEVIATION 16.849 | 75.60 kg STANDARD_DEVIATION 13.001 | 74.59 kg STANDARD_DEVIATION 16.828 | 88.71 kg STANDARD_DEVIATION 12.486 | 87.15 kg STANDARD_DEVIATION 8.892 | 80.36 kg STANDARD_DEVIATION 13.611 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 8 | 0 / 8 | 0 / 8 | 0 / 8 |
| other Total, other adverse events | 4 / 7 | 6 / 8 | 5 / 8 | 4 / 8 | 4 / 8 |
| serious Total, serious adverse events | 0 / 7 | 0 / 8 | 0 / 8 | 0 / 8 | 0 / 8 |
Outcome results
Primary
The Occurrence of Adverse Events (AE) Following Administration of G03-52-01 to the Final Follow-up Visit
Determine number of AEs after dosing (Cohort 4)
Time frame: day 0 to day 180
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 10mg of G03-52-01 | The Occurrence of Adverse Events (AE) Following Administration of G03-52-01 to the Final Follow-up Visit | 8 Number of AEs |
| 25mg of G03-52-01 | The Occurrence of Adverse Events (AE) Following Administration of G03-52-01 to the Final Follow-up Visit | 6 Number of AEs |
Primary
The Occurrence of Adverse Events (AE) Following Administration of G03-52-01 to the Final Follow-up Visit
Determine number of AEs after dosing (Cohorts 1-3)
Time frame: day 0 to day 120
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 10mg of G03-52-01 | The Occurrence of Adverse Events (AE) Following Administration of G03-52-01 to the Final Follow-up Visit | 8 Number of AEs |
| 25mg of G03-52-01 | The Occurrence of Adverse Events (AE) Following Administration of G03-52-01 to the Final Follow-up Visit | 10 Number of AEs |
| 50 mg of G03-52-01 | The Occurrence of Adverse Events (AE) Following Administration of G03-52-01 to the Final Follow-up Visit | 11 Number of AEs |
| Pooled Placebo | The Occurrence of Adverse Events (AE) Following Administration of G03-52-01 to the Final Follow-up Visit | 6 Number of AEs |
Primary
The Occurrence of Changes From Baseline in Physical Examination, Vital Signs and Clinical Safety Laboratory Values Following Administration of G03-52-01 to the Final Follow-up Visit.
Determine number of changes from baseline (Cohort 4)
Time frame: day 0 to day 180
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 10mg of G03-52-01 | The Occurrence of Changes From Baseline in Physical Examination, Vital Signs and Clinical Safety Laboratory Values Following Administration of G03-52-01 to the Final Follow-up Visit. | 1 Number of events |
Primary
The Occurrence of Changes From Baseline in Physical Examination, Vital Signs and Clinical Safety Laboratory Values Following Administration of G03-52-01 to the Final Follow-up Visit.
Determine number of changes from baseline (Cohorts 1-3)
Time frame: day 0 to day 120
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 10mg of G03-52-01 | The Occurrence of Changes From Baseline in Physical Examination, Vital Signs and Clinical Safety Laboratory Values Following Administration of G03-52-01 to the Final Follow-up Visit. | 7 Number of events |
| 25mg of G03-52-01 | The Occurrence of Changes From Baseline in Physical Examination, Vital Signs and Clinical Safety Laboratory Values Following Administration of G03-52-01 to the Final Follow-up Visit. | 3 Number of events |
| 50 mg of G03-52-01 | The Occurrence of Changes From Baseline in Physical Examination, Vital Signs and Clinical Safety Laboratory Values Following Administration of G03-52-01 to the Final Follow-up Visit. | 7 Number of events |
| Pooled Placebo | The Occurrence of Changes From Baseline in Physical Examination, Vital Signs and Clinical Safety Laboratory Values Following Administration of G03-52-01 to the Final Follow-up Visit. | 4 Number of events |
Primary
The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit.
Determine number of SAEs after dosing (Cohorts 1-3)
Time frame: day 0 to day 120
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 10mg of G03-52-01 | The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit. | 0 Number of SAEs |
| 25mg of G03-52-01 | The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit. | 0 Number of SAEs |
| 50 mg of G03-52-01 | The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit. | 0 Number of SAEs |
| Pooled Placebo | The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit. | 0 Number of SAEs |
Primary
The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit.
Determine number of SAEs after dosing (Cohort 4)
Time frame: day 0 to day 180
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 10mg of G03-52-01 | The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit. | 0 Number of SAEs |
| 25mg of G03-52-01 | The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit. | 0 Number of SAEs |
Secondary
Anti-BoNT A Area Under the Plasma Concentration Versus Time Curve (AUC)
ELISA/ECLA assessment of PK (Cohorts 1-3)
Time frame: pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection, and on days 4, 8, 15, 30, 45, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT A Area Under the Plasma Concentration Versus Time Curve (AUC) | 76121.9 h*ng/mL | Geometric Coefficient of Variation 32.64 |
| 25mg of G03-52-01 | Anti-BoNT A Area Under the Plasma Concentration Versus Time Curve (AUC) | 211066.2 h*ng/mL | Geometric Coefficient of Variation 29.35 |
| 50 mg of G03-52-01 | Anti-BoNT A Area Under the Plasma Concentration Versus Time Curve (AUC) | 346965.1 h*ng/mL | Geometric Coefficient of Variation 33.76 |
Secondary
Anti-BoNT A Area Under the Plasma Concentration Versus Time Curve (AUC)
ELISA/ECLA assessment of PK (Cohort 4)
Time frame: pre-injection, 6 hours post injection, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT A Area Under the Plasma Concentration Versus Time Curve (AUC) | 598555.3 h*ng/mL | Geometric Coefficient of Variation 77.05 |
Secondary
Anti-BoNT A Peak Plasma Concentration (Cmax)
ELISA/ECLA assessment of PK (Cohort 4)
Time frame: pre-injection, 6 hours post injection, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT A Peak Plasma Concentration (Cmax) | 1372.08 ng/mL | Geometric Coefficient of Variation 33.69 |
Secondary
Anti-BoNT A Peak Plasma Concentration (Cmax)
ELISA/ECLA assessment of PK (Cohorts 1-3)
Time frame: pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection, and on days 4, 8, 15, 30, 45, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT A Peak Plasma Concentration (Cmax) | 123.06 ng/mL | Geometric Coefficient of Variation 17.66 |
| 25mg of G03-52-01 | Anti-BoNT A Peak Plasma Concentration (Cmax) | 362.845 ng/mL | Geometric Coefficient of Variation 33.605 |
| 50 mg of G03-52-01 | Anti-BoNT A Peak Plasma Concentration (Cmax) | 678.635 ng/mL | Geometric Coefficient of Variation 44.12 |
Secondary
Anti-BoNT A Time to Achieve Peak Concentration of the Drug After Administration (Tmax)
ELISA/ECLA assessment of PK (Cohorts 1-3)
Time frame: pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection, and on days 4, 8, 15, 30, 45, 60, 90, and 120
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 84 hrs |
| 25mg of G03-52-01 | Anti-BoNT A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 71.71 hrs |
| 50 mg of G03-52-01 | Anti-BoNT A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 71.34 hrs |
Secondary
Anti-BoNT A Time to Achieve Peak Concentration of the Drug After Administration (Tmax)
ELISA/ECLA assessment of PK (Cohort 4)
Time frame: pre-injection, 6 hours post injection, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 47.87 hrs |
Secondary
Anti-BoNT B Area Under the Plasma Concentration Versus Time Curve (AUC)
ELISA/ECLA assessment of PK (Cohort 1-3)
Time frame: pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection and on days 4, 8, 15, 30, 45, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT B Area Under the Plasma Concentration Versus Time Curve (AUC) | 120541.5 h*ng/mL | Geometric Coefficient of Variation 30.55 |
| 25mg of G03-52-01 | Anti-BoNT B Area Under the Plasma Concentration Versus Time Curve (AUC) | 338924.7 h*ng/mL | Geometric Coefficient of Variation 28.11 |
| 50 mg of G03-52-01 | Anti-BoNT B Area Under the Plasma Concentration Versus Time Curve (AUC) | 530432.5 h*ng/mL | Geometric Coefficient of Variation 29.64 |
Secondary
Anti-BoNT B Area Under the Plasma Concentration Versus Time Curve (AUC)
ELISA/ECLA assessment of PK (Cohort 4)
Time frame: pre-injection, 6 hours post injection, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT B Area Under the Plasma Concentration Versus Time Curve (AUC) | 1259300 h*ng/mL | Geometric Coefficient of Variation 30.16 |
Secondary
Anti-BoNT B Peak Plasma Concentration (Cmax)
ELISA/ECLA assessment of PK (Cohorts 1-3)
Time frame: pre-injection, 2,4, 8, 24, 48, and 72 hours post injection, and on days 4, 8, 15, 30, 45, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT B Peak Plasma Concentration (Cmax) | 133.49 ng/mL | Geometric Coefficient of Variation 18.73 |
| 25mg of G03-52-01 | Anti-BoNT B Peak Plasma Concentration (Cmax) | 401.25 ng/mL | Geometric Coefficient of Variation 30.44 |
| 50 mg of G03-52-01 | Anti-BoNT B Peak Plasma Concentration (Cmax) | 722.73 ng/mL | Geometric Coefficient of Variation 37.85 |
Secondary
Anti-BoNT B Peak Plasma Concentration (Cmax)
ELISA/ECLA assessment of PK (Cohort 4)
Time frame: pre-injection, 6 hours post injection, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT B Peak Plasma Concentration (Cmax) | 1668.88 ng/mL | Geometric Coefficient of Variation 26.73 |
Secondary
Anti-BoNT B Time to Achieve Peak Concentration of the Drug After Administration (Tmax)
ELISA/ECLA assessment of PK (Cohorts 1-3)
Time frame: pre-injection, 2, 4, 8, 24, 48, and 72 hours post injection, and on days 4, 8, 15, 30, 45, 60, 90, and 120
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 128 hrs |
| 25mg of G03-52-01 | Anti-BoNT B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 107.83 hrs |
| 50 mg of G03-52-01 | Anti-BoNT B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 79.58 hrs |
Secondary
Anti-BoNT B Time to Achieve Peak Concentration of the Drug After Administration (Tmax)
ELISA/ECLA assessment of PK (Cohort 4)
Time frame: pre-injection, 6 hours post injection, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 10mg of G03-52-01 | Anti-BoNT B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 72.59 hrs |
Secondary
Anti-drug Antibodies (ADA)
To assess the number of participants with positive anti-drug antibody levels (Cohort 4)
Time frame: pre-dose, days 45, 60, 90, 120, and 180
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 10mg of G03-52-01 | Anti-drug Antibodies (ADA) | 5 Participants |
Secondary
Anti-drug Antibodies (ADA)
To assess the number of participants with positive anti-drug antibody levels (Cohorts 1-3)
Time frame: pre-dose, days 15, 30, 45, 60, 90, and 120
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 10mg of G03-52-01 | Anti-drug Antibodies (ADA) | 5 Participants |
| 25mg of G03-52-01 | Anti-drug Antibodies (ADA) | 6 Participants |
| 50 mg of G03-52-01 | Anti-drug Antibodies (ADA) | 4 Participants |
Secondary
Serotype A Area Under the Plasma Concentration Versus Time Curve (AUC)
MNA assessment of PD (Cohorts 1-3)
Time frame: pre-dose, days 4, 30, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Serotype A Area Under the Plasma Concentration Versus Time Curve (AUC) | 23.530 h*U/L | Geometric Coefficient of Variation 174.61 |
| 25mg of G03-52-01 | Serotype A Area Under the Plasma Concentration Versus Time Curve (AUC) | 82.821 h*U/L | Geometric Coefficient of Variation 189.37 |
| 50 mg of G03-52-01 | Serotype A Area Under the Plasma Concentration Versus Time Curve (AUC) | 281.393 h*U/L | Geometric Coefficient of Variation 33.21 |
Secondary
Serotype A Area Under the Plasma Concentration Versus Time Curve (AUC)
MNA assessment of PD (Cohort 4)
Time frame: pre-dose, 2 hours post-dose, days 4, 30, 45, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Serotype A Area Under the Plasma Concentration Versus Time Curve (AUC) | 1106.673 h*U/L | Geometric Coefficient of Variation 57.81 |
Secondary
Serotype A Peak Plasma Concentration (Cmax)
MNA assessment of PD (Cohorts 1-3)
Time frame: pre-dose, days 4, 30, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Serotype A Peak Plasma Concentration (Cmax) | 0.0977 U/L | Geometric Coefficient of Variation 46.37 |
| 25mg of G03-52-01 | Serotype A Peak Plasma Concentration (Cmax) | 0.288 U/L | Geometric Coefficient of Variation 47.14 |
| 50 mg of G03-52-01 | Serotype A Peak Plasma Concentration (Cmax) | 0.658 U/L | Geometric Coefficient of Variation 49.29 |
Secondary
Serotype A Peak Plasma Concentration (Cmax)
MNA assessment of PD (Cohort 4)
Time frame: pre-dose, 2 hours post-dose, days 4, 30, 45, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Serotype A Peak Plasma Concentration (Cmax) | 2.07 U/L | Geometric Coefficient of Variation 79.84 |
Secondary
Serotype A Time to Achieve Peak Concentration of the Drug After Administration (Tmax)
MNA assessment of PD (Cohort 4)
Time frame: pre-dose, 2 hours post-dose, days 4, 30, 45, 60, 90, and 120
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 10mg of G03-52-01 | Serotype A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 95.76 hrs |
Secondary
Serotype A Time to Achieve Peak Concentration of the Drug After Administration (Tmax)
MNA assessment of PD (Cohorts 1-3)
Time frame: pre-dose, days 4, 30, 60, 90, and 120
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 10mg of G03-52-01 | Serotype A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 96 hrs |
| 25mg of G03-52-01 | Serotype A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 95.89 hrs |
| 50 mg of G03-52-01 | Serotype A Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 96 hrs |
Secondary
Serotype B Area Under the Plasma Concentration Versus Time Curve (AUC)
MNA assessment of PD (Cohorts 1-3)
Time frame: pre-dose, days 4, 30, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Serotype B Area Under the Plasma Concentration Versus Time Curve (AUC) | 608.306 h*U/L | Geometric Coefficient of Variation 49.6 |
| 25mg of G03-52-01 | Serotype B Area Under the Plasma Concentration Versus Time Curve (AUC) | 1208.471 h*U/L | Geometric Coefficient of Variation 53.63 |
| 50 mg of G03-52-01 | Serotype B Area Under the Plasma Concentration Versus Time Curve (AUC) | 1939.427 h*U/L | Geometric Coefficient of Variation 40.93 |
Secondary
Serotype B Area Under the Plasma Concentration Versus Time Curve (AUC)
MNA assessment of PD (Cohort 4)
Time frame: pre-dose, 2 hours post-dose, days 4, 30, 45, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Serotype B Area Under the Plasma Concentration Versus Time Curve (AUC) | 2940.815 h*U/L | Geometric Coefficient of Variation 33.14 |
Secondary
Serotype B Peak Plasma Concentration (Cmax)
MNA assessment of PD (Cohort 4)
Time frame: pre-dose, 2 hours post-dose, days 4, 30, 45, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Serotype B Peak Plasma Concentration (Cmax) | 3.63 U/L | Geometric Coefficient of Variation 20.85 |
Secondary
Serotype B Peak Plasma Concentration (Cmax)
MNA assessment of PD (Cohorts 1-3)
Time frame: pre-dose, days 4, 30, 60, 90, and 120
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 10mg of G03-52-01 | Serotype B Peak Plasma Concentration (Cmax) | 0.630 U/L | Geometric Coefficient of Variation 100.37 |
| 25mg of G03-52-01 | Serotype B Peak Plasma Concentration (Cmax) | 1.30 U/L | Geometric Coefficient of Variation 53.38 |
| 50 mg of G03-52-01 | Serotype B Peak Plasma Concentration (Cmax) | 2.25 U/L | Geometric Coefficient of Variation 57.9 |
Secondary
Serotype B Time to Achieve Peak Concentration of the Drug After Administration (Tmax)
MNA assessment of PD (Cohort 4)
Time frame: pre-dose, 2 hours post-dose, days 4, 30, 45, 60, 90, and 120
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 10mg of G03-52-01 | Serotype B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 95.88 hrs |
Secondary
Serotype B Time to Achieve Peak Concentration of the Drug After Administration (Tmax)
MNA assessment of PD (Cohorts 1-3)
Time frame: pre-dose, days 4, 30, 60, 90, and 120
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 10mg of G03-52-01 | Serotype B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 96 hrs |
| 25mg of G03-52-01 | Serotype B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 96.78 hrs |
| 50 mg of G03-52-01 | Serotype B Time to Achieve Peak Concentration of the Drug After Administration (Tmax) | 96.01 hrs |